Cassava Sciences stock plummeted Monday — wiping out more than three-quarters of its value — after the company's Alzheimer's treatment failed in Phase 3 testing. Please watch the video at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback